marine drugs

IMPACT FACTOR 4.9

Indexed in: PubMed

CITESCORE 9.6

an Open Access Journal by MDPI

Marine-Derived Compounds Applied in Intestinal Diseases

Guest Editors:

Dr. Gaurav Rajauria
School of Agriculture and Food Science, University College Dublin, Lyons Research Farm, Celbridge, Ireland

Prof. Dr. Torres Sweeney
School of Veterinary Medicine, Veterinary Science Centre, University College Dublin, Belfield Dublin 4, Ireland

Prof. Dr. John O'Doherty
School of Agriculture and Food Science, University College Dublin, Belfield, Dublin 4, Ireland

Deadline for manuscript submissions:
closed (31 December 2020)

Message from the Guest Editors

Chronic inflammation is thought to play critical roles in the pathogenesis of various intestinal diseases in humans and animals. Measures to reduce intestinal dysfunction have focused on dietary inclusion of antibiotics and/or drugs, frequently with adverse side effects. In the hunt for alternatives, natural animal- and plant-derived products offer hope for the discovery of bioactive molecules or compounds that can alleviate intestinal disorders. The biological and chemical diversity in the marine environment represents an excellent source for isolating bioactive compounds from microalgae, macroalgae (seaweed), cyanobacteria, fungi, or small invertebrates, such as sponges and molluscs. Bioactive compounds like polysaccharides, polyphenols, diterpenes, steroids, alkaloids, fatty acids, proteins, and other chemical compounds, isolated from marine organisms, exhibit potential activity against intestinal disorders. This proposed Special Issue of *Marine Drugs* will cover the entire scope of marine-derived compounds that are being explored for gastrointestinal disorders and diseases both in human and animals.

marine drugs

IMPACT FACTOR 4.9 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
𝕏@Marine_Drugs